phrykt

CervoMed Inc. (CRVO): who owns it and who trades it

As of Nov 9, 2026, CRVO insiders reported 7 purchases worth $3.3M in the last 12 months. The largest buyer was Joshua S Boger (Director), with $3M.

Latest filing Nov 9, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

In the last 12 months, CRVO insiders reported $3.3M of open-market purchases and $0 of sales.

Purchases, 12 months
$3.3M
7 trades, 4 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
Jun 11, 2026
Filed Jun 15, 2026

Purchases and sales by month

$3M$3MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Jun 11, 2026Joshua S BogerDirectorPurchase955,414$3.14$3MForm 4
Nov 18, 2025Matthew WintonChief Commercial and BusPurchase1,500$7.95$11.9KForm 4
Nov 18, 2025William Robert ElderCFOPurchase2,500$8.32$20.8KForm 4
Nov 17, 2025Matthew WintonChief Commercial and BusPurchase3,500$8.43$29.5KForm 4
Nov 17, 2025Sylvie GregoireDirectorPurchase10,793$8.46$91.3KForm 4
Nov 17, 2025Sylvie GregoireDirectorPurchase10,807$8.46$91.4KForm 4
Nov 17, 2025William Robert ElderCFOPurchase1,000$8.45$8.4KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Joshua S BogerDirector, 10% owner$3M–Jun 11, 2026
Sylvie GregoireDirector, 10% owner$183K–Nov 17, 2025
Matthew WintonChief Commercial and Business$41.4K–Nov 18, 2025
William Robert ElderCFO, GC & Secretary$29.2K–Nov 18, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CRVO short interest

Moderate short interest. 8.0% of CRVO shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went up 336%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.21M CRVO shares were sold short, 8.0% of the shares outstanding, up 0.4% from the report before. At the average daily volume of 260,594 shares, buying them all back would take about 4.7 trading days (days to cover).

Shares short, % of all shares

8.02%May 15Oct 309.91%

Days to cover

4.7May 15Oct 308.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.21M8.02%+0%260,5944.7
Oct 15, 20261.21M7.99%-10%408,3703.0
Sep 30, 20261.34M8.86%+9%189,9577.0
Sep 15, 20261.23M8.12%-8%171,8487.2
Aug 31, 20261.33M8.79%+38%274,3884.8
Aug 14, 2026962,5766.37%+16%413,5852.3
Jul 31, 2026832,4258.99%+1%305,9022.7
Jul 15, 2026827,4558.94%+2%806,3371.0
Jun 30, 2026807,5628.72%+135%32.17M1.0
Jun 15, 2026343,8463.71%+31%1.02M1.0
May 29, 2026262,8062.84%-5%92,0352.9
May 15, 2026277,8973.00%-1%50,5045.5

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

CervoMed company events

CervoMed filed 27 reports on Form 8-K in the last 12 months, all of them routine, such as results and vote reports. The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Oct 29, 2026AnnouncementThe information set forth in the first paragraph of, and under the headings “ Alzheimer's Research & Therapy Publication” and “ Cells Publication” in, the Company’s press release on October 29, 2026, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K. 2 Item 9.01. Filing
  3. Oct 14, 2026AnnouncementShared information with investors. Filing
  4. Oct 13, 2026AnnouncementThe information set forth in the first paragraph of, and in the first, second, and fourth paragraphs under the heading, “Initial Biomarker Data from the Phase 2a Study in nfvPPA” in, the Company’s press release issued on October 12, 2026, is incorporated by reference into this Item 8.01 of this… Filing
  5. Oct 9, 2026AnnouncementShared information with investors. Filing
  6. Sep 28, 2026AnnouncementThe information set forth in the first and second paragraphs of, and under the heading “Supporting Data and Details” in, the Company’s press release on September 28, 2026, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K. Item 9.01. Filing
  7. Sep 10, 2026AnnouncementWe issued a press release announcing that initial results from our Phase 2a clinical trial of neflamapimod in nonfluent variant primary progressive aphasia have been accepted as a late-breaking oral presentation at the Annual Meeting of the International Society of Frontotemporal Dementias taking… Filing
  8. Aug 10, 2026ResultsReleased financial results. Filing
  9. Aug 4, 2026AnnouncementThe information set forth in the first and fourth paragraphs of the Company’s press release issued on August 4, 2026, is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press… Filing
  10. Jul 14, 2026AnnouncementThe information set forth in the first and third paragraphs of, and under the headings “Analyses Reinforce Observed Treatment Effect of Neflamapimod in ‘Pure’ DLB and Support Planned Phase 3 Dose” and “Neflamapimod Demonstrated Durable Slowing of Basal Forebrain Atrophy,” and in the first, second… Filing
  11. Jul 9, 2026AnnouncementThe information set forth in the first and third paragraphs of, and under the headings “Recent Nature Neuroscience publication supports inhibition of p38α as potential therapeutic approach in FTD,” and “Interim results from the Phase 2a clinical trial to be presented at CTAD” in, the Company’s… Filing
  12. Jun 22, 2026AnnouncementThe Company closed the Offering. 2 Item 9.01. Filing
  13. Jun 22, 2026AgreementCervoMed Inc., a Delaware corporation, entered into a Securities Purchase Agreement with the investors named therein, pursuant to which the Company agreed to issue and sell, in a registered direct offering by the Company directly to the Investors, 2,500,000 shares of the Company’s common stock, par… Filing
  14. Jun 18, 2026AnnouncementCervoMed Inc. received a notice of allowance from the United States Patent and Trademark Office related to a new patent protecting the Company’s use of its drug candidate, neflamapimod, for the treatment of dementia with Lewy bodies in patients with no substantial Alzheimer’s disease-like tau… Filing
  15. Jun 15, 2026AnnouncementShared information with investors. Filing
  16. Jun 10, 2026AgreementCervoMed Inc. entered into a securities purchase agreement with certain accredited investors named therein (each, an “Investor” and collectively, the “Investors”), for the private placement of an aggregate of 3,360,377 units, each Unit comprised of (i) (A) one share of the Company’s common stock… Filing
  17. Jun 9, 2026VoteReported shareholder vote results. Filing
  18. May 18, 2026ResultsReleased financial results. Filing
  19. Apr 22, 2026AnnouncementThe information set forth in the first paragraph of, and under the heading “Summary of Data Presented at AAN” in, the Company’s April 22, 2026, press release is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits (d) Exhibits… Filing
  20. Apr 7, 2026AnnouncementShared information with investors. Filing
  21. Mar 23, 2026AnnouncementShared information with investors. Filing
  22. Mar 19, 2026AnnouncementThe information set forth in the first paragraph of, and under the headings “New analyses of data from RewinD-LB Trial stratified by plasma pTau181 subset demonstrate greater treatment effect with reduced likelihood of AD co-pathology,” and “New PK/PD analyses of Phase 2b clinical data” in, the… Filing
  23. Mar 17, 2026ResultsReleased financial results. Filing
  24. Mar 4, 2026AnnouncementThe information set forth in the first two paragraphs of the Company’s March 4, 2026, press release is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, issued March… Filing
  25. Feb 18, 2026AnnouncementThe information set forth in the first two paragraphs of the Company’s February 18, 2026, press release is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K. Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Press Release, issued… Filing
  26. Jan 8, 2026AnnouncementShared information with investors. Filing
  27. Dec 5, 2025AnnouncementThe information set forth, (i) with respect to the December 2 Press Release, in the first two paragraphs and under the heading, “Treatment Benefit Associated with Biomarker Measurements,” and (ii) with respect to the December 4 Press Release, in the first paragraph and under the heading, “Results… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

CervoMed financials

Questions about CervoMed Inc. (CRVO) stock

Are CRVO insiders buying or selling?

In the last 12 months, CRVO insiders reported 7 open-market purchases worth $3.3M and no sales. The latest trade was on Jun 11, 2026. See every trade.

What is the short interest in CRVO?

As of Oct 30, 2026, 1.21M CRVO shares were sold short, 8.0% of the shares outstanding, up 0.4% from the report before. At the average daily volume of 260,594 shares, buying them all back would take about 4.7 trading days (days to cover). See the history.

Executive pay

CervoMed's chief executive was paid a total of $1M for the year ended Dec 31, 2025, up 1% from $1M the year before. In the last 12 months, CervoMed's executives and directors bought $3.4M of stock on the open market and sold none.

Chief executive, total pay$1MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$1.5MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$669KThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.